Trial Purpose

This is a study evaluating the efficacy, safety and pharmacokinetics of MK-1084 in participants with advanced solid tumours with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.

Learn More on



When speaking to your doctor, please have the trial identifier number available.

About The Study

Trial Phase Icon

Phase 1

Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.

Trial start Icon


  • Actual study start date 17 December 2021
  • Estimated primary completion date 5 February 2026
  • Estimated study completion date 5 February 2026


Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon


Advanced Solid Tumours

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.